Medicine:Rheumatic fever

From HandWiki
Short description: Post-streptococcal inflammatory disease
Rheumatic fever
Other namesAcute rheumatic fever (ARF)
Rheumatic heart disease, gross pathology 20G0013 lores.jpg
Rheumatic heart disease at autopsy with characteristic findings (thickened mitral valve, thickened chordae tendineae, hypertrophied left ventricular myocardium)
SymptomsFever, multiple painful joints, involuntary muscle movements, erythema marginatum[1]
ComplicationsRheumatic heart disease, heart failure, atrial fibrillation, infection of the valves[1]
Usual onset2–4 weeks after a streptococcal throat infection, age 5–14 years[2]
CausesAutoimmune disease triggered by Streptococcus pyogenes[1]
Risk factorsGenetics, malnutrition, poverty[1]
Diagnostic methodBased on symptoms and infection history[3]
PreventionAntibiotics for strep throat, improved sanitation[1][4]
TreatmentProlonged periods of antibiotics, valve replacement surgery, valve repair[1]
Frequency325,000 children a year[1]
Deaths319,400 (2015)[5]

Rheumatic fever (RF) is an inflammatory disease that can involve the heart, joints, skin, and brain.[1] The disease typically develops two to four weeks after a streptococcal throat infection.[2] Signs and symptoms include fever, multiple painful joints, involuntary muscle movements, and occasionally a characteristic non-itchy rash known as erythema marginatum.[1] The heart is involved in about half of the cases.[1] Damage to the heart valves, known as rheumatic heart disease (RHD), usually occurs after repeated attacks but can sometimes occur after one.[1] The damaged valves may result in heart failure, atrial fibrillation and infection of the valves.[1]

Rheumatic fever may occur following an infection of the throat by the bacterium Streptococcus pyogenes.[1] If the infection is left untreated, rheumatic fever occurs in up to three percent of people.[6] The underlying mechanism is believed to involve the production of antibodies against a person's own tissues.[1] Due to their genetics, some people are more likely to get the disease when exposed to the bacteria than others.[1] Other risk factors include malnutrition and poverty.[1] Diagnosis of RF is often based on the presence of signs and symptoms in combination with evidence of a recent streptococcal infection.[3]

Treating people who have strep throat with antibiotics, such as penicillin, decreases the risk of developing rheumatic fever.[4] In order to avoid antibiotic misuse this often involves testing people with sore throats for the infection; however, testing might not be available in the developing world.[1] Other preventive measures include improved sanitation.[1] In those with rheumatic fever and rheumatic heart disease, prolonged periods of antibiotics are sometimes recommended.[1] Gradual return to normal activities may occur following an attack.[1] Once RHD develops, treatment is more difficult.[1] Occasionally valve replacement surgery or valve repair is required.[1] Otherwise complications are treated as usual.[1]

Rheumatic fever occurs in about 325,000 children each year and about 33.4 million people currently have rheumatic heart disease.[1][7] Those who develop RF are most often between the ages of 5 and 14,[1] with 20% of first-time attacks occurring in adults.[8] The disease is most common in the developing world and among indigenous peoples in the developed world.[1] In 2015 it resulted in 319,400 deaths down from 374,000 deaths in 1990.[5][9] Most deaths occur in the developing world where as many as 12.5% of people affected may die each year.[1] Descriptions of the condition are believed to date back to at least the 5th century BCE in the writings of Hippocrates.[10] The disease is so named because its symptoms are similar to those of some rheumatic disorders.[11]

Signs and symptoms

A culture positive case of streptococcal pharyngitis with typical tonsillar exudate in a 16-year-old

The disease typically develops two to four weeks after a throat infection.[2] Symptoms include: fever, painful joints with those joints affected changing with time, involuntary muscle movements, and occasionally a characteristic non-itchy rash known as erythema marginatum. The heart is involved in about half of the cases. Damage to the heart valves usually occurs only after multiple attacks but may occasionally occur after a single case of RF. The damaged valves may result in heart failure and also increase the risk of atrial fibrillation and infection of the valves.[1]


Rheumatic fever is a systemic disease affecting the connective tissue around arterioles, and can occur after an untreated strep throat infection, specifically due to group A streptococcus (GAS), Streptococcus pyogenes. The similarity between antigens of Streptococcus pyogenes and multiple cardiac proteins can cause a life-threatening type II hypersensitivity reaction.[12] Usually, self reactive B cells remain anergic in the periphery without T cell co-stimulation. During a streptococcal infection, mature antigen-presenting cells such as B cells present the bacterial antigen to CD4+T cells which differentiate into helper T2 cells. Helper T2 cells subsequently activate the B cells to become plasma cells and induce the production of antibodies against the cell wall of Streptococcus. However the antibodies may also react against the myocardium and joints,[13] producing the symptoms of rheumatic fever. S. pyogenes is a species of aerobic, cocci, gram-positive bacteria that are non-motile, non-spore forming, and forms chains and large colonies.[14]

S. pyogenes has a cell wall composed of branched polymers which sometimes contain M protein, a virulence factor that is highly antigenic. The antibodies which the immune system generates against the M protein may cross-react with heart muscle cell protein myosin,[15] heart muscle glycogen and smooth muscle cells of arteries, inducing cytokine release and tissue destruction. However, the only proven cross-reaction is with perivascular connective tissue.[citation needed] This inflammation occurs through direct attachment of complement and Fc receptor-mediated recruitment of neutrophils and macrophages. Characteristic Aschoff bodies, composed of swollen eosinophilic collagen surrounded by lymphocytes and macrophages can be seen on light microscopy. The larger macrophages may become Anitschkow cells or Aschoff giant cells. Rheumatic valvular lesions may also involve a cell-mediated immunity reaction as these lesions predominantly contain T-helper cells and macrophages.[16]

In rheumatic fever, these lesions can be found in any layer of the heart causing different types of carditis. The inflammation may cause a serofibrinous pericardial exudate described as "bread-and-butter" pericarditis, which usually resolves without sequelae. Involvement of the endocardium typically results in fibrinoid necrosis and wart formation along the lines of closure of the left-sided heart valves. Warty projections arise from the deposition, while subendocardial lesions may induce irregular thickenings called MacCallum plaques.[citation needed]

Rheumatic heart disease

Pathophysiology of rheumatic heart disease
Micrograph showing an Aschoff body (right of image), as seen in rheumatic heart disease. H&E stain

Chronic rheumatic heart disease (RHD) is characterized by repeated inflammation with fibrinous repair. The cardinal anatomic changes of the valve include leaflet thickening, commissural fusion, and shortening and thickening of the tendinous cords.[16] It is caused by an autoimmune reaction to Group A β-hemolytic streptococci (GAS) that results in valvular damage.[17] Fibrosis and scarring of valve leaflets, commissures and cusps leads to abnormalities that can result in valve stenosis or regurgitation.[18] The inflammation caused by rheumatic fever, usually during childhood, is referred to as rheumatic valvulitis. About half of patients with rheumatic fever develop inflammation involving valvular endothelium.[19] The majority of morbidity and mortality associated with rheumatic fever is caused by its destructive effects on cardiac valve tissue.[18] The complicated pathogenesis of RHD is not fully understood, though it has been observed to use molecular mimicry via group A streptococci carbohydrates and genetic predisposition involving HLA Class II genes that trigger autoimmune reactions.[20]

Molecular mimicry occurs when epitopes are shared between host antigens and Streptococcus antigens.[21] This causes an autoimmune reaction against native tissues in the heart that are incorrectly recognized as "foreign" due to the cross-reactivity of antibodies generated as a result of epitope sharing. The valvular endothelium is a prominent site of lymphocyte-induced damage. CD4+ T cells are the major effectors of heart tissue autoimmune reactions in RHD.[22] Normally, T cell activation is triggered by the presentation of bacterial antigens. In RHD, molecular mimicry results in incorrect T cell activation, and these T lymphocytes can go on to activate B cells, which will begin to produce self-antigen-specific antibodies. This leads to an immune response attack mounted against tissues in the heart that have been misidentified as pathogens. Rheumatic valves display increased expression of VCAM-1, a protein that mediates the adhesion of lymphocytes.[23] Self-antigen-specific antibodies generated via molecular mimicry between human proteins and streptococcal antigens up-regulate VCAM-1 after binding to the valvular endothelium. This leads to the inflammation and valve scarring observed in rheumatic valvulitis, mainly due to CD4+ T cell infiltration.[23]

While the mechanisms of genetic predisposition remain unclear, a few genetic factors have been found to increase susceptibility to autoimmune reactions in RHD. The dominant contributors are a component of MHC class II molecules, found on lymphocytes and antigen-presenting cells, specifically the DR and DQ alleles on human chromosome 6.[24] Certain allele combinations appear to increase RHD autoimmune susceptibility. Human leukocyte antigen (HLA) class II allele DR7 (HLA-DR7) is most often associated with RHD, and its combination with certain DQ alleles is seemingly associated with the development of valvular lesions.[24] The mechanism by which MHC class II molecules increase a host's susceptibility to autoimmune reactions in RHD is unknown, but it is likely related to the role HLA molecules play in presenting antigens to T cell receptors, thus triggering an immune response. Also found on human chromosome 6 is the cytokine TNF-α which is also associated with RHD.[24] High expression levels of TNF-α may exacerbate valvular tissue inflammation, because as this cytokine circulates in the bloodstream, it triggers the activation of multiple pathways that stimulate further pro-inflammatory cytokine secretion.[25] Mannose-binding lectin (MBL) is an inflammatory protein involved in pathogen recognition. Different variants of MBL2 gene regions are associated in RHD. RHD-induced mitral valve stenosis has been associated with MBL2 alleles encoding for high production of MBL.[26] Aortic valve regurgitation in RHD patients has been associated with different MBL2 alleles that encode for low production of MBL.[27] In addition, the allele IGHV4-61, located on chromosome 14, which helps code for the immunoglobulin heavy chain (IgH) is linked to greater susceptibility to RHD because it may affect protein structure of the IgH.[28] Other genes are also being investigated to better understand the complexity of autoimmune reactions that occur in RHD.[citation needed]


Streptococcus pyogenes bacteria (Pappenheim's stain), the trigger for rheumatic fever

The original method of diagnosing rheumatic heart disease was through heart auscultation, specifically listening for the sound of blood regurgitation from possibly dysfunctional valves. However, studies have shown that echocardiography is much more efficient in detecting RHD due to its high sensitivity. An echocardiogram has the ability to detect signs of RHD before the development of more obvious symptoms such as tissue scarring and stenosis.[29] Modified Jones criteria were first published in 1944 by T. Duckett Jones, MD.[30] They have been periodically revised by the American Heart Association in collaboration with other groups.[31] According to revised Jones criteria, the diagnosis of rheumatic fever can be made when two of the major criteria, or one major criterion plus two minor criteria, are present along with evidence of streptococcal infection: elevated or rising antistreptolysin O titre[32] or anti-DNase B.[8][33] A recurrent episode is also diagnosed when three minor criteria are present.[34] Exceptions are chorea and indolent carditis, each of which by itself can indicate rheumatic fever.[35][36][37] An April 2013 review article in the Indian Journal of Medical Research stated that echocardiographic and Doppler (E & D) studies, despite some reservations about their utility, have identified a massive burden of rheumatic heart disease, which suggests the inadequacy of the 1992 Jones' criteria. E & D studies have identified subclinical carditis in patients with rheumatic fever, as well as in follow-ups of rheumatic heart disease patients who initially presented as having isolated cases of Sydenham's chorea.[38] Signs of a preceding streptococcal infection include: recent scarlet fever, raised antistreptolysin O or other streptococcal antibody titre, or positive throat culture.[39] The last revision of 2015 suggested variable diagnostic criteria in low-risk and high-risk populations to avoid overdiagnosis in the first category and underdiagnosis in the last one.[34] Low-risk populations were defined as those with acute rheumatic fever annual incidence ≤2 per 100 000 school-aged children or all-age rheumatic heart disease prevalence of ≤1 per 1000.[34] All other populations were categorised as having a moderate or high risk.[34]

Major criteria

  1. Joint manifestations are the unique clinical signs that have different implications for different population-risk categories : Only polyarthritis[40] (a temporary migrating inflammation of the large joints, usually starting in the legs and migrating upwards) is considered as a major criterion in low-risk populations, whereas monoarthritis, polyarthritis and polyarthralgia (joint pain without swelling) are all included as major criteria in high-risk populations.[34]
  2. Carditis: Carditis can involve the pericardium (pericarditis which resolves without sequelae), some regions of the myocardium (which might not provoke systolic dysfunction), and more consistently the endocardium in the form of valvulitis.[41] Carditis is diagnosed clinically (palpitations, shortness of breath, heart failure, or a new heart murmur) or by echocardiography/Doppler studies revealing mitral or aortic valvulitis. Both of clinical and subclinical carditis are now considered a major criterion.[34][41]
  3. Subcutaneous nodules: Painless, firm collections of collagen fibers over bones or tendons. They commonly appear on the back of the wrist, the outside elbow, and the front of the knees.[citation needed]
  4. Erythema marginatum: A long-lasting reddish rash that begins on the trunk or arms as macules, which spread outward and clear in the middle to form rings, which continue to spread and coalesce with other rings, ultimately taking on a snake-like appearance. This rash typically spares the face and is made worse with heat.[citation needed]
  5. Sydenham's chorea (St. Vitus' dance): A characteristic series of involuntary rapid movements of the face and arms. This can occur very late in the disease for at least three months from onset of infection.[citation needed]

Minor criteria

  1. Arthralgia: Polyarthralgia in low-risk populations and monoarthralgia in others.[34] However, joint manifestations cannot be considered in both major and minor categories in the same patient.[34]
  2. Fever: ≥ 38.5 °C (101.3 °F) in low-incidence populations and ≥ 38 °C (100.4 °F) in high-risk populations.[34]
  3. Raised erythrocyte sedimentation rate (≥60 mm in the first hour in lox-risk populations and ≥30 mm/h in others) or C reactive protein (>3.0 mg/dL).[34]
  4. ECG showing a prolonged PR interval[34][39][42] after accounting for age variability (Cannot be included if carditis is present as a major symptom)


Rheumatic fever can be prevented by effectively and promptly treating strep throat with antibiotics.[43]

In those who have previously had rheumatic fever, antibiotics in a preventative manner are occasionally recommended.[43] As of 2017 the evidence to support long term antibiotics in those with underlying disease is poor.[44]

The American Heart Association suggests that dental health be maintained, and that people with a history of bacterial endocarditis, a heart transplant, artificial heart valves, or "some types of congenital heart defects" may wish to consider long-term antibiotic prophylaxis.[45]


The management of rheumatic fever is directed toward the reduction of inflammation with anti-inflammatory medications such as aspirin or corticosteroids. Individuals with positive cultures for strep throat should also be treated with antibiotics.[40]

Aspirin is the drug of choice and should be given at high doses.[46]

One should watch for side effects like gastritis and salicylate poisoning. In children and teenagers, the use of aspirin and aspirin-containing products can be associated with Reye's syndrome, a serious and potentially deadly condition. The risks, benefits, and alternative treatments must always be considered when administering aspirin and aspirin-containing products in children and teenagers. Ibuprofen for pain and discomfort and corticosteroids for moderate to severe inflammatory reactions manifested by rheumatic fever should be considered in children and teenagers.[citation needed]


No vaccines are currently available to protect against S. pyogenes infection, although research is underway to develop one.[47] Difficulties in developing a vaccine include the wide variety of strains of S. pyogenes present in the environment and the large amount of time and people that will be needed for appropriate trials for safety and efficacy of the vaccine.[48]


People with positive cultures for Streptococcus pyogenes should be treated with penicillin as long as allergy is not present. The use of antibiotics will not alter cardiac involvement in the development of rheumatic fever.[40] Some suggest the use of benzathine benzylpenicillin.[citation needed]

Monthly injections of long-acting penicillin must be given for a period of five years in patients having one attack of rheumatic fever. If there is evidence of carditis, the length of therapy may be up to 40 years. Another important cornerstone in treating rheumatic fever includes the continual use of low-dose antibiotics (such as penicillin, sulfadiazine, or erythromycin) to prevent recurrence.[citation needed]


While corticosteroids are often used, evidence to support this is poor.[1] Salicylates are useful for pain.[citation needed]

Steroids are reserved for cases where there is evidence of an involvement of the heart. The use of steroids may prevent further scarring of tissue and may prevent the development of sequelae such as mitral stenosis.[citation needed]

Heart failure

Some patients develop significant carditis which manifests as congestive heart failure. This requires the usual treatment for heart failure: ACE inhibitors, diuretics, beta blockers, and digoxin. Unlike typical heart failure, rheumatic heart failure responds well to corticosteroids.


Deaths from rheumatic heart disease per million persons in 2012
Disability-adjusted life year for rheumatic heart disease per 100,000 inhabitants in 2004.[49]
  no data
  less than 20
  more than 330

About 33 million people are affected by rheumatic heart disease with an additional 47 million having asymptomatic damage to their heart valves.[44] As of 2010 globally it resulted in 345,000 deaths, down from 463,000 in 1990.[50]

In Western countries, rheumatic fever has become fairly rare since the 1960s, probably due to the widespread use of antibiotics to treat streptococcus infections. While it has been far less common in the United States since the beginning of the 20th century, there have been a few outbreaks since the 1980s.[51] The disease is most common among Indigenous Australians (particularly in central and northern Australia), Māori, and Pacific Islanders, and is also common in Sub-Saharan Africa, Latin America, the Indian subcontinent, and North Africa.[52]

Rheumatic fever primarily affects children between ages 5 and 17 years and occurs approximately 20 days after strep throat. In up to a third of cases, the underlying strep infection may not have caused any symptoms.[citation needed]

The rate of development of rheumatic fever in individuals with untreated strep infection is estimated to be 3%. The incidence of recurrence with a subsequent untreated infection is substantially greater (about 50%).[53] The rate of development is far lower in individuals who have received antibiotic treatment. Persons who have had a case of rheumatic fever have a tendency to develop flare-ups with repeated strep infections.[citation needed]

The recurrence of rheumatic fever is relatively common in the absence of maintenance of low dose antibiotics, especially during the first three to five years after the first episode. Recurrent bouts of rheumatic fever can lead to valvular heart disease. Heart complications may be long-term and severe, particularly if valves are involved. In countries in Southeast-Asia, sub-Saharan Africa, and Oceania, the percentage of people with rheumatic heart disease detected by listening to the heart was 2.9 per 1000 children and by echocardiography it was 12.9 per 1000 children.[54][55][56][57] Echocardiographic screening among children and timely initiation of secondary antibiotic prophylaxis in children with evidence of early stages of rheumatic heart disease may be effective to reduce the burden of rheumatic heart disease in endemic regions.[58]

See also


  1. 1.00 1.01 1.02 1.03 1.04 1.05 1.06 1.07 1.08 1.09 1.10 1.11 1.12 1.13 1.14 1.15 1.16 1.17 1.18 1.19 1.20 1.21 1.22 1.23 1.24 1.25 1.26 1.27 1.28 Marijon, E; Mirabel, M; Celermajer, DS; Jouven, X (10 March 2012). "Rheumatic heart disease.". The Lancet 379 (9819): 953–64. doi:10.1016/S0140-6736(11)61171-9. PMID 22405798. 
  2. 2.0 2.1 2.2 Lee, KY; Rhim, JW; Kang, JH (March 2012). "Kawasaki disease: laboratory findings and an immunopathogenesis on the premise of a "protein homeostasis system".". Yonsei Medical Journal 53 (2): 262–75. doi:10.3349/ymj.2012.53.2.262. PMID 22318812. 
  3. 3.0 3.1 "Rheumatic Fever 1997 Case Definition". 3 February 2015. 
  4. 4.0 4.1 Spinks, Anneliese; Glasziou, Paul P.; Del Mar, Chris B. (2021-12-09). "Antibiotics for treatment of sore throat in children and adults". The Cochrane Database of Systematic Reviews 2021 (12): CD000023. doi:10.1002/14651858.CD000023.pub5. ISSN 1469-493X. PMID 34881426. 
  5. 5.0 5.1 ((GBD 2015 Mortality and Causes of Death Collaborators)) (8 October 2016). "Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015.". The Lancet 388 (10053): 1459–1544. doi:10.1016/S0140-6736(16)31012-1. PMID 27733281. 
  6. Ashby, Carol Turkington, Bonnie Lee (2007). The encyclopedia of infectious diseases (3rd ed.). New York: Facts On File. p. 292. ISBN 9780816075072. "The risk of severe complications is the primary concern with strep throat, and the reason why it is so important to be properly diagnosed and treated. One of the most serious complications is rheumatic fever, a disease that affects up to 3 percent of those with untreated strep infection. Rheumatic fever can lead to rheumatic heart disease." 
  7. ((GBD 2015 Disease and Injury Incidence and Prevalence Collaborators)) (8 October 2016). "Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015.". The Lancet 388 (10053): 1545–1602. doi:10.1016/S0140-6736(16)31678-6. PMID 27733282. 
  8. 8.0 8.1 Kumar, Vinay; Abbas, Abul K; Fausto, Nelson; Mitchell, Richard N (2007). Robbins Basic Pathology (8th ed.). Saunders Elsevier. pp. 403–6. ISBN 978-1-4160-2973-1. 
  9. ((GBD 2013 Mortality and Causes of Death Collaborators)) (17 December 2014). "Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013.". The Lancet 385 (9963): 117–171. doi:10.1016/S0140-6736(14)61682-2. PMID 25530442. 
  10. Quinn, RW (1991). "Did scarlet fever and rheumatic fever exist in Hippocrates' time?". Reviews of Infectious Diseases 13 (6): 1243–4. doi:10.1093/clinids/13.6.1243. PMID 1775859. 
  11. "rheumatic fever" at Dorland's Medical Dictionary
  12. "4.2 Biocompatibility and the Relationship to Standards: Meaning and Scope of Biomaterials Testing". Comprehensive Biomaterials II. Elsevier. 2017. pp. 7–29. 
  13. Abbas, Abul K. et al. (2004). Basic immunology: functions and disorders of the immune system (2 ed.). Philadelphia, Pennsylvania: Elsevier Saunders. ISBN 978-1-4160-2403-3. 
  14. "Streptococcus pyogenes – Pathogen Safety Data Sheets". Public Health Agency of Canada. 18 February 2011. 
  15. "Mimicry in recognition of cardiac myosin peptides by heart-intralesional T cell clones from rheumatic heart disease". J. Immunol. 176 (9): 5662–70. May 2006. doi:10.4049/jimmunol.176.9.5662. PMID 16622036. 
  16. 16.0 16.1 Cotran, Ramzi S.; Kumar, Vinay; Fausto, Nelson; Nelso Fausto; Robbins, Stanley L.; Abbas, Abul K. (2005). Robbins and Cotran pathologic basis of disease. St. Louis, Mo: Elsevier Saunders. ISBN 978-0-7216-0187-8. 
  17. Kaplan, MH; Bolande, R; Rakita, L; Blair, J (1964). "Presence of Bound Immunoglobulins and Complement in the Myocardium in Acute Rheumatic Fever. Association with Cardiac Failure". The New England Journal of Medicine 271 (13): 637–45. doi:10.1056/NEJM196409242711301. PMID 14170842. 
  18. 18.0 18.1 Brice, Edmund A. W; Commerford, Patrick J. (2005). "Rheumatic Fever and Valvular Heart Disease". in Rosendorff, Clive. Essential Cardiology: Principles and Practice. Totowa, New Jersey: Humana Press. pp. 545–563. doi:10.1007/978-1-59259-918-9_30. ISBN 978-1-59259-918-9. 
  19. Caldas, AM; Terreri, MT; Moises, VA; Silva, CM; Len, CA; Carvalho, AC; Hilário, MO (2008). "What is the true frequency of carditis in acute rheumatic fever? A prospective clinical and Doppler blind study of 56 children with up to 60 months of follow-up evaluation". Pediatric Cardiology 29 (6): 1048–53. doi:10.1007/s00246-008-9242-z. PMID 18825449. 
  20. Guilherme, Luiza; Kalil, Jorge; Cunningham, Madeleine (January 2006). "Molecular mimicry in the autoimmune pathogenesis of rheumatic heart disease" (in en). Autoimmunity 39 (1): 31–39. doi:10.1080/08916930500484674. ISSN 0891-6934. PMID 16455580. 
  21. Guilherme, L; Kalil, J; Cunningham, M (2006). "Molecular mimicry in the autoimmune pathogenesis of rheumatic heart disease". Autoimmunity 39 (1): 31–9. doi:10.1080/08916930500484674. PMID 16455580. 
  22. Kemeny, E; Grieve, T; Marcus, R; Sareli, P; Zabriskie, JB (1989). "Identification of mononuclear cells and T cell subsets in rheumatic valvulitis". Clinical Immunology and Immunopathology 52 (2): 225–37. doi:10.1016/0090-1229(89)90174-8. PMID 2786783. 
  23. 23.0 23.1 Roberts, S; Kosanke, S; Terrence Dunn, S; Jankelow, D; Duran, CM; Cunningham, MW (2001). "Pathogenic mechanisms in rheumatic carditis: Focus on valvular endothelium". The Journal of Infectious Diseases 183 (3): 507–11. doi:10.1086/318076. PMID 11133385. 
  24. 24.0 24.1 24.2 Stanevicha, V; Eglite, J; Sochnevs, A; Gardovska, D; Zavadska, D; Shantere, R (2003). "HLA class II associations with rheumatic heart disease among clinically homogeneous patients in children in Latvia". Arthritis Research & Therapy 5 (6): R340–R346. doi:10.1186/ar1000. PMID 14680508. 
  25. Middleton, Francis M.; McGregor, Reuben; Webb, Rachel H.; Wilson, Nigel J.; Moreland, Nicole J. (2022-12-01). "Cytokine imbalance in acute rheumatic fever and rheumatic heart disease: Mechanisms and therapeutic implications" (in en). Autoimmunity Reviews 21 (12): 103209. doi:10.1016/j.autrev.2022.103209. ISSN 1568-9972. PMID 36228998. 
  26. Schafranski, MD; Pereira Ferrari, L; Scherner, D; Torres, R; Jensenius, JC; De Messias-Reason, IJ (2008). "High-producing MBL2 genotypes increase the risk of acute and chronic carditis in patients with history of rheumatic fever". Molecular Immunology 45 (14): 3827–31. doi:10.1016/j.molimm.2008.05.013. PMID 18602696. 
  27. Ramasawmy, R; Spina, GS; Fae, KC; Pereira, AC; Nisihara, R; Messias Reason, IJ; Grinberg, M; Tarasoutchi, F et al. (2008). "Association of Mannose-Binding Lectin Gene Polymorphism but Not of Mannose-Binding Serine Protease 2 with Chronic Severe Aortic Regurgitation of Rheumatic Etiology". Clinical and Vaccine Immunology 15 (6): 932–936. doi:10.1128/CVI.00324-07. PMID 18400978. 
  28. Muhamed, Babu; Parks, Tom; Sliwa, Karen (March 2020). "Genetics of rheumatic fever and rheumatic heart disease" (in en). Nature Reviews Cardiology 17 (3): 145–154. doi:10.1038/s41569-019-0258-2. ISSN 1759-5010. PMID 31519994. 
  29. Dougherty, Scott; Khorsandi, Maziar; Herbst, Philip (2017-01-01). "Rheumatic heart disease screening: Current concepts and challenges" (in en). Annals of Pediatric Cardiology 10 (1): 39–49. doi:10.4103/0974-2069.197051. ISSN 0974-2069. PMID 28163427. PMC 5241843.;year=2017;volume=10;issue=1;spage=39;epage=49;aulast=Dougherty;type=0. 
  30. Jones, T Duckett (1944). "The diagnosis of rheumatic fever". JAMA 126 (8): 481–4. doi:10.1001/jama.1944.02850430015005. 
  31. Ferrieri, P; Jones Criteria Working, Group (2002). "Proceedings of the Jones Criteria workshop". Circulation (Jones Criteria Working Group) 106 (19): 2521–3. doi:10.1161/01.CIR.0000037745.65929.FA. PMID 12417554. 
  32. "Antistreptolysin O (ASO)". 24 July 2020. 
  33. "Anti-DNase B". 28 June 2021. 
  34. 34.00 34.01 34.02 34.03 34.04 34.05 34.06 34.07 34.08 34.09 34.10 Gewitz Michael H.; Baltimore Robert S.; Tani Lloyd Y.; Sable Craig A.; Shulman Stanford T.; Carapetis Jonathan; Remenyi Bo; Taubert Kathryn A. et al. (2015-05-19). "Revision of the Jones Criteria for the Diagnosis of Acute Rheumatic Fever in the Era of Doppler Echocardiography". Circulation 131 (20): 1806–1818. doi:10.1161/CIR.0000000000000205. PMID 25908771. 
  35. Parrillo, Steven J. "Rheumatic Fever". eMedicine. DO, FACOEP, FACEP. 
  36. "Guidelines for the diagnosis of rheumatic fever. Jones Criteria, 1992 update". JAMA (Special Writing Group of the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease of the Council on Cardiovascular Disease in the Young of the American Heart Association) 268 (15): 2069–73. 1992. doi:10.1001/jama.1992.03490150121036. PMID 1404745. 
  37. Saxena, Anita (2000). "Diagnosis of rheumatic fever: Current status of Jones criteria and role of echocardiography". Indian Journal of Pediatrics 67 (4): 283–6. doi:10.1007/BF02758174. PMID 11129913. 
  38. Kumar, RK; Tandon, R (2013). "Rheumatic fever & rheumatic heart disease: The last 50 years". The Indian Journal of Medical Research 137 (4): 643–658. PMID 23703332. 
  39. 39.0 39.1 Ed Boon, Davidson's General Practice of Medicine, 20th edition. P. 617.
  40. 40.0 40.1 40.2 "WHO | Rheumatic fever and rheumatic heart disease". 
  41. 41.0 41.1 Karthikeyan, Ganesan; Guilherme, Luiza (July 2018). "Acute rheumatic fever". The Lancet 392 (10142): 161–174. doi:10.1016/s0140-6736(18)30999-1. ISSN 0140-6736. PMID 30025809. 
  42. Aly, Ashraf (2008). "Rheumatic Fever". Core Concepts of Pediatrics. University of Texas. 
  43. 43.0 43.1 Gerber, MA; Baltimore, RS; Eaton, CB; Gewitz, M; Rowley, AH; Shulman, ST; Taubert, KA (24 March 2009). "Prevention of rheumatic fever and diagnosis and treatment of acute Streptococcal pharyngitis: a scientific statement from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young, the Interdisciplinary Council on Functional Genomics and Translational Biology, and the Interdisciplinary Council on Quality of Care and Outcomes Research: endorsed by the American Academy of Pediatrics.". Circulation 119 (11): 1541–51. doi:10.1161/circulationaha.109.191959. PMID 19246689. 
  44. 44.0 44.1 Nulu, S; Bukhman, G; Kwan, GF (February 2017). "Rheumatic Heart Disease: The Unfinished Global Agenda.". Cardiology Clinics 35 (1): 165–180. doi:10.1016/j.ccl.2016.08.006. PMID 27886787. 
  45. "What About My Child and Rheumatic Fever?". American Heart Association. 
  46. "Aspirin Monograph for Professionals -". American Society of Health-System Pharmacists. 
  47. "Collaboration aims for rheumatic fever vaccine". September 18, 2014. 
  48. "Initiative for Vaccine Research (IVR) – Group A Streptococcus". World Health Organization. 
  49. "WHO Disease and injury country estimates". World Health Organization. 2009. 
  50. "Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010". Lancet 380 (9859): 2095–128. 2012. doi:10.1016/S0140-6736(12)61728-0. PMID 23245604. PMC 10790329. 
  51. "Rheumatic fever". NLM/NIH. 
  52. "Rheumatic heart disease". Menzies Institute for Medical Research. 
  53. Porth, Carol (2007). Essentials of pathophysiology: concepts of altered health states. Hagerstown, MD: Lippincott Williams & Wilkins. ISBN 978-0-7817-7087-3. 
  54. Marijon, Eloi; Ou, Phalla; Celermajer, David S.; Ferreira, Beatriz; Mocumbi, Ana Olga; Jani, Dinesh; Paquet, Christophe; Jacob, Sophie et al. (2007-08-02). "Prevalence of rheumatic heart disease detected by echocardiographic screening". The New England Journal of Medicine 357 (5): 470–476. doi:10.1056/NEJMoa065085. ISSN 1533-4406. PMID 17671255. 
  55. Rothenbühler, Martina; O'Sullivan, Crochan J.; Stortecky, Stefan; Stefanini, Giulio G.; Spitzer, Ernest; Estill, Janne; Shrestha, Nikesh R.; Keiser, Olivia et al. (2014-12-01). "Active surveillance for rheumatic heart disease in endemic regions: a systematic review and meta-analysis of prevalence among children and adolescents". The Lancet Global Health 2 (12): e717–726. doi:10.1016/S2214-109X(14)70310-9. ISSN 2214-109X. PMID 25433627. 
  56. Shrestha NR et al. (2016-03-02). "Prevalence of subclinical rheumatic heart disease in eastern nepal: A school-based cross-sectional study". JAMA Cardiology 1 (1): 89–96. doi:10.1001/jamacardio.2015.0292. ISSN 2380-6583. PMID 27437661. 
  57. Beaton, Andrea; Okello, Emmy; Lwabi, Peter; Mondo, Charles; McCarter, Robert; Sable, Craig (2012-06-26). "Echocardiography screening for rheumatic heart disease in Ugandan schoolchildren". Circulation 125 (25): 3127–3132. doi:10.1161/CIRCULATIONAHA.112.092312. ISSN 1524-4539. PMID 22626741. 
  58. Karki, Prahlad; Uranw, Surendra; Bastola, Santosh; Mahato, Rajan; Shrestha, Nikesh Raj; Sherpa, Kunjang et al. (2021). "Effectiveness of Systematic Echocardiographic Screening for Rheumatic Heart Disease in Nepalese Schoolchildren: A Cluster Randomized Clinical Trial". JAMA Cardiology 6 (4): 420–426. doi:10.1001/jamacardio.2020.7050. ISSN 2380-6583. PMID 33471029. 

External links

External resources